692 results
Page 6 of 35
6-K
EX-99.1
9mbioaifzxil 17i6
23 Mar 15
Live Filing
12:00am
6-K
EX-99.1
xxk13j6nck69
25 Feb 15
Live Filing
12:00am
6-K
EX-99.1
gtz6d9qe
24 Feb 15
TEVA ANNOUNCES POSITIVE RESULTS FOR TEV-48125 IN PHASE IIb CHRONIC MIGRAINE STUDY MEETING PRIMARY AND SECONDARY ENDPOINTS
12:00am
6-K
EX-99.1
wi77g
23 Feb 15
Live Filing
12:00am
6-K
EX-99.1
phsksy15y k8lm3yopbq
5 Feb 15
Teva Reports Fourth Quarter and Full Year 2014 Results
12:00am
6-K
EX-99.1
roz3v
11 Dec 14
Teva Provides 2015 Business Outlook
12:00am
6-K
EX-99.1
tb2cs9ug4brnwn
4 Dec 14
Live Filing
12:00am
6-K
EX-99.1
04lbzmmla6kb8 yc
26 Nov 14
Prof. Yitzhak Peterburg Elected Chairman of Teva’s Board of Directors
12:00am
6-K
EX-99.1
eyufu7
30 Oct 14
Teva Reports Third Quarter 2014 Results
12:00am
6-K
y3zor9gl4tymrtj81
30 Oct 14
Current report (foreign)
12:00am
6-K
EX-99.1
dm9sy
8 Oct 14
Live Filing
12:00am
6-K
EX-99.1
6wrexl
6 Oct 14
Teva Announces Results of Strategic Review of Core Specialty Therapeutic Areas
12:00am
6-K
EX-99.1
bv89div xu
12 Sep 14
Teva Presents Gene Expression Analysis at Joint ACTRIMS-ECTRIMS Meeting Demonstrating COPAXONE® (glatiramer acetate injection) Has a Complex Profile
12:00am
6-K
EX-99.1
lo8hzni289r2s 3v5gg
12 Sep 14
Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting
12:00am
6-K
EX-99.1
npfwuj8t
11 Sep 14
Live Filing
12:00am
6-K
EX-99.1
v4ofxf2 x410
8 Sep 14
Successful Completion of Phase Iii Program for Teva’s Reslizumab
12:00am
6-K
EX-99.1
0lnsdl2rf2j45 6rs
3 Sep 14
Live Filing
12:00am
6-K
EX-99.1
0qe8h02g7htevozddez1
2 Sep 14
Live Filing
12:00am
6-K
EX-99.1
fxt 5tgl3uc
21 Jul 14
Live Filing
12:00am